Swedish Medical Center (Ballard Campus)

Seattle, WA

Sorting 7 by

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Accepting patients

iMMagine-3

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • Randomization
  • Phase 3

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
  • Monoclonal Antibody
  • CD38
  • Phase 3

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Randomization
  • Phase 3

Accepting patients

LINKER-MM1

First in Human (FIH) Study of Linvoseltamab (REGN5458) in Patients With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1/2
  • Has results

Not currently accepting

MajesTEC-4

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
  • Bispecific Antibody
  • BCMA
  • Phase 3

Accepting patients

Early Detection Blood Tests

Blinded Reference Set for Multicancer Early Detection Blood Tests
  • Observational Trial